Celcuity announced new data from the Phase 3 VIKTORIA-1 trial showing significant improvements in progression-free survival and objective response rates for gedatolisib in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback